Eurazeo Valuation
Is EUQ undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of EUQ when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: EUQ (€69.7) is trading below our estimate of fair value (€449.54)
Significantly Below Fair Value: EUQ is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for EUQ?
Key metric: As EUQ is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is EUQ's PS Ratio? | |
|---|---|
| PS Ratio | 15.1x |
| Sales | €337.89m |
| Market Cap | €5.12b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 19.1x |
| Enterprise Value/EBITDA | 327.5x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does EUQ's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 9.3x | ||
CHG CHAPTERS Group | 6.1x | 20.2% | €528.8m |
PZS Scherzer | 9.8x | 10.0% | €65.3m |
T2G Tradegate Wertpapierhandelsbank | 18.1x | n/a | €2.2b |
HYQ Hypoport | 3.3x | 11.5% | €1.4b |
EUQ Eurazeo | 15.1x | 50.7% | €5.1b |
Price-To-Sales vs Peers: EUQ is expensive based on its Price-To-Sales Ratio (15.1x) compared to the peer average (9.3x).
Price to Sales Ratio vs Industry
How does EUQ's PS Ratio compare vs other companies in the DE Diversified Financial Industry?
Price-To-Sales vs Industry: EUQ is expensive based on its Price-To-Sales Ratio (15.1x) compared to the European Diversified Financial industry average (1.9x).
Price to Sales Ratio vs Fair Ratio
What is EUQ's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 15.1x |
| Fair PS Ratio | 6x |
Price-To-Sales vs Fair Ratio: EUQ is expensive based on its Price-To-Sales Ratio (15.1x) compared to the estimated Fair Price-To-Sales Ratio (6x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | €69.70 | €91.67 +31.5% | 5.6% | €100.00 | €83.00 | n/a | 6 |
| Nov ’25 | €70.15 | €92.00 +31.1% | 6.7% | €100.00 | €80.00 | n/a | 6 |
| Oct ’25 | €73.75 | €92.00 +24.7% | 6.7% | €100.00 | €80.00 | n/a | 6 |
| Sep ’25 | €71.25 | €92.33 +29.6% | 6.0% | €100.00 | €82.00 | n/a | 6 |
| Aug ’25 | €71.20 | €94.00 +32.0% | 6.8% | €100.00 | €82.00 | n/a | 6 |
| Jul ’25 | €76.40 | €94.00 +23.0% | 6.4% | €100.00 | €83.00 | n/a | 6 |
| Jun ’25 | €78.00 | €94.00 +20.5% | 6.4% | €100.00 | €83.00 | n/a | 6 |
| May ’25 | €84.45 | €93.50 +10.7% | 7.8% | €100.00 | €79.00 | n/a | 6 |
| Apr ’25 | €81.20 | €93.50 +15.1% | 7.8% | €100.00 | €79.00 | n/a | 6 |
| Mar ’25 | €78.05 | €92.75 +18.8% | 8.5% | €102.00 | €75.00 | n/a | 8 |
| Feb ’25 | €78.65 | €92.63 +17.8% | 8.2% | €100.00 | €75.00 | n/a | 8 |
| Jan ’25 | €72.05 | €90.25 +25.3% | 8.3% | €99.00 | €73.00 | n/a | 8 |
| Dec ’24 | €69.35 | €90.25 +30.1% | 8.3% | €99.00 | €73.00 | n/a | 8 |
| Nov ’24 | €53.85 | €89.13 +65.5% | 9.0% | €98.00 | €69.00 | €70.15 | 8 |
| Oct ’24 | €56.20 | €89.75 +59.7% | 7.2% | €98.00 | €74.00 | €73.75 | 8 |
| Sep ’24 | €54.70 | €90.38 +65.2% | 5.3% | €98.00 | €80.00 | €71.25 | 8 |
| Aug ’24 | €55.30 | €90.88 +64.3% | 5.3% | €98.00 | €80.00 | €71.20 | 8 |
| Jul ’24 | €64.50 | €94.38 +46.3% | 7.6% | €104.00 | €80.00 | €76.40 | 8 |
| Jun ’24 | €63.95 | €94.38 +47.6% | 7.6% | €104.00 | €80.00 | €78.00 | 8 |
| May ’24 | €64.55 | €93.14 +44.3% | 8.0% | €104.00 | €80.00 | €84.45 | 7 |
| Apr ’24 | €65.45 | €93.14 +42.3% | 8.0% | €104.00 | €80.00 | €81.20 | 7 |
| Mar ’24 | €64.50 | €87.14 +35.1% | 10.1% | €100.00 | €70.00 | €78.05 | 7 |
| Feb ’24 | €64.30 | €87.14 +35.5% | 10.1% | €100.00 | €70.00 | €78.65 | 7 |
| Jan ’24 | €58.60 | €87.14 +48.7% | 10.1% | €100.00 | €70.00 | €72.05 | 7 |
| Dec ’23 | €61.10 | €87.14 +42.6% | 10.1% | €100.00 | €70.00 | €69.35 | 7 |
| Nov ’23 | €58.25 | €90.50 +55.4% | 11.0% | €100.00 | €69.00 | €53.85 | 7 |
Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.
Discover undervalued companies
ORIX
JP¥3.8t
Provides diversified financial services in Japan, the United States, Asia, Europe, Australasia, and the Middle East.
OIX
JP¥20.40
7D
1.0%
1Y
22.2%
Mutares SE KGaA
€484.6m
A private equity firm specializing in investments in secondary direct, special situations, bridge financing, recapitalization, distressed/vulture, management succession, reorganization, carve-outs, turnarounds, spin-offs and re-funding.
MUX
€22.40
7D
1.1%
1Y
-29.3%
Merchants Bancorp
US$1.9b
Operates as the diversified bank holding company in the United States.
3KD
US$39.20
7D
5.9%
1Y
31.5%